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or less (NMR-2000): an analysis using data from the UK and 
The Gambia
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Summary
Background 78% of neonatal deaths occur in sub-Saharan Africa and southern Asia, among which, more than 80% 
are in low birthweight babies. Existing neonatal mortality risk scores have primarily been developed for high-resource 
settings. The aim of this study was to develop and validate a score that is practicable for low-income and middle-
income countries to predict in-hospital mortality among neonates born weighing 2000 g or less using datasets from 
the UK and The Gambia.
Methods This analysis used retrospective data held in the UK National Neonatal Research Database from 187 neonatal 
units, and data from the Edward Francis Small Teaching Hospital (EFSTH), Banjul, The Gambia. In the UK dataset, 
neonates were excluded if birthweight was more than 2000 g; if the neonate was admitted aged more than 6 h or 
following discharge; if the neonate was stillborn; if the neonate died in delivery room; or if they were moribund on 
admission. The Gambian dataset included all neonates weighing less than 2000 g who were admitted between 
May 1, 2018, and Sept 30, 2019, who were screened for but not enrolled in the Early Kangaroo Mother Care Trial. 
18 studies were reviewed to generate a list of 84 potential parameters. We derived a model to score in-hospital neonatal 
mortality risk using data from 55 029 admissions to a random sample of neonatal units in England and Wales from 
Jan 1, 2010, to Dec 31, 2016. All candidate variables were included in a complete multivariable model, which was 
progressively simplified using reverse stepwise selection. We validated the new score (NMR-2000) on 40 329 admissions 
to the remaining units between the same dates and 14 818 admissions to all units from Jan 1, to Dec 31, 2017. We also 
validated the score on 550 neonates admitted to the EFSTH in The Gambia.
Findings 18 candidate variables were selected for inclusion in the modelling process. The final model included 
three parameters: birthweight, admission oxygen saturation, and highest level of respiratory support within 24 h of 
birth. NMR-2000 had very good discrimination and goodness-of-fit across the UK samples, with a c-index of 
0·8859–0·8930 and a Brier score of 0·0232–0·0271. Among Gambian neonates, the model had a c-index of 0·8170 
and a Brier score of 0·1688. Predictive ability of the simplified integer score was similar to the model using regression 
coefficients, with c-indices of 0·8903 in the UK full validation sample and 0·8082 in the Gambian validation sample.
Interpretation NMR-2000 is a validated mortality risk score for hospitalised neonates weighing 2000 g or less in 
settings where pulse oximetry is available. The score is accurate and simplified for bedside use. NMR-2000 requires 
further validation using a larger dataset from low-income and middle-income countries but has the potential to 
improve individual and population-level neonatal care resource allocation.
Funding Bill & Melinda Gates Foundation; Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Wellcome Trust; and Joint Global Health Trials scheme of Department of Health and Social Care, 
Department for International Development, Medical Research Council, and Wellcome Trust.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
An estimated 2·5 million neonatal deaths occurred in 
2018, accounting for 47% of deaths among children 
younger than 5 years.1 The burden of neonatal mortality 
is unequally distributed, with nearly 80% of these 
deaths occurring in sub-Saharan Africa and southern 
Asia.1 Between 2000 and 2015, neonatal mortality 
declined more slowly than mortality among children 
aged 1–59 months. This disparity was particularly 
notable in sub-Saharan Africa, where the annual 
mortality reduction for newborn babies was less than 
half of that for 1–59 month-olds.2 Slow progress in this 
region might be related to high incidences of preterm 
birth (<37 completed weeks of gestation) and low 
birthweight (≤2000 g),3,4 poor access to care for 
neonates,5,6 and health system capacity issues, including 
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shortages of skilled providers, essential supplies, and 
basic equipment.6–8
More than 80% of neonatal deaths in sub-Saharan 
Africa and southern Asia occur in babies with a low 
birthweight.9 Low birthweight can result from being 
preterm, being small for their gestational age, or both. 
Mortality is twice as high in full-term neonates who are 
small for their gestational age than in full-term neonates 
who are of average size, and 15 times higher in preterm 
neonates who are small for their gestational age than in 
babies with either characteristic alone.10 The lower the 
birthweight and gestational age, the higher the mortality 
risk.9 Around 86% of neonates born at fewer than 
28 weeks’ gestation, and 41% of those born at 28–31 weeks, 
will die without access to intensive care;11 more than 75% 
of neonates in sub-Saharan Africa and southern Asia 
have no access to such care.7 Estimates suggest that 
neonatal special care,5,7 including resuscitation, kangaroo 
mother care, feeding support or intravenous fluids, and 
management of respiratory distress, infections, and 
jaundice, could prevent 70% of preterm deaths and 
decrease prematurity-related causes of neonatal mortality 
by 58%.12
Various systems for scoring illness severity and 
mortality risk in neonates have been developed, primarily 
for high-income settings (appendix p 6). Therapy-based 
approaches, such as the Neonatal Therapeutic Inter-
vention Scoring System (NTISS),13 categorise illness 
severity by the quantity and type of therapies 
administered. By contrast, the Score for Neonatal Acute 
Physiology (SNAP),14,15 the Transport Risk Index of 
Physiologic Stability (TRIPS),16 and other physiology-
based approaches use objective, measurable parameters 
that vary with illness severity, such as blood pressure. 
Related models, such as the Clinical Risk Index for 
Babies (CRIB),17,18 combine physiological parameters 
with perinatal factors, such as birthweight, to provide an 
overall mortality risk score. SNAP and CRIB are the 
most widely used systems and have been extensively 
validated.19
Research in context
Evidence before this study
2·5 million neonatal deaths occur each year, among which 78% 
are in sub-Saharan Africa and southern Asia. More than 80% of 
these deaths occur in babies with a low birthweight who are 
small because they are preterm, small for their gestational age, 
or both. There has been slow progress in reducing neonatal 
mortality, which accounts for nearly half of deaths in children 
younger than 5 years, highlighting the need for scale-up of 
effective interventions for neonates who are at risk. We searched 
PubMed for studies published between Jan 1, 1992, and July 31, 
2019, with the search terms “infant, newborn”, and “infant 
mortality”, or “infant, newborn, diseases, and mortality”, or 
“infant, premature, diseases, and mortality”, or “hospital 
mortality”, and “severity of illness index”, or “risk assessment”, 
or “predictive value of tests”, or “outcome assessment”. Multiple 
risk scores for neonatal mortality, illness severity, and clinical 
instability have been developed for intensive care settings. Most 
of these risk scores are not feasible for low-income and middle-
income countries, because they rely on laboratory-derived and 
therapy-derived parameters that are frequently unavailable, or 
on clinical observations that are not reliably measurable. A need 
remains for a highly predictive tool, feasible for use in resource-
constrained settings, to help providers objectively assess 
mortality risk in the most vulnerable babies.
Added value of this study
Using population-wide data from 110 176 neonates admitted 
to 187 hospitals across England and Wales, this study has 
derived and validated a mortality risk score for neonates 
weighing 2000 g or less (NMR-2000). To our knowledge, this 
is the largest dataset used to develop and validate a neonatal 
mortality risk score. NMR-2000 uses data on three 
parameters: birthweight, oxygen saturation (peripheral 
capillary oxygen) at admission, and highest level of 
respiratory support at any point within 24 h of birth. 
The model had very good discrimination and goodness-of-fit 
across the development and UK validation samples, with a 
c-index of 0·8859–0·8930 and a Brier score of 0·0232–0·0271. 
The simplified integer score, which can be measured and 
calculated at the bedside, showed predictive ability similar to 
the model using regression coefficients. In the Gambian 
dataset, which included 550 neonates at one hospital, the 
model had good discrimination and overall goodness-of-fit, 
with a c-index of 0·8170 and a Brier score of 0·1688. 
The simplified integer score showed similar performance, 
with a c-index of 0·8082. Complete data for scoring were 
available for 83% of neonates. These findings indicate that 
the NMR-2000 is valid for use in health facilities where 
pulse oximetry is available and underscore the fact that 
implementation in low-income and middle-income countries 
would require sensitisation regarding documentation of the 
three parameters used in the model.
Implications of all the available evidence
To reduce neonatal mortality worldwide, there is an urgent 
need to scale-up evidence-based interventions targeting the 
major causes of death. Our risk score could expedite 
recognition of severe illness and enable targeted delivery of 
care to small and vulnerable neonates, increasing effectiveness 
and efficiency of facility-based neonatal care in low-income 
and middle-income countries. Further research is required to 
validate NMR-2000 in low-resource settings using a larger 
sample, and to evaluate its usefulness for clinical decision 
making. The score has the potential to inform resource use, 
including nursing workload.
See Online for appendix
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Notably, none of the aforementioned systems are 
practicable for routine use in low-income and middle-
income countries (LMICs), because these systems rely 
on laboratory-derived and therapy-derived measures that 
are often not available, or on clinical observations 
that are not reliably measurable in these settings.20–22 
The simplified age-weight-sex (SAWS) score is the 
only validated neonatal mortality score designed for 
low-resource settings. Among a derivation cohort of 
428 neonates weighing 1500 g or less in Bangladesh 
and Egypt, the SAWS was reported to have moderate 
discrimination for in-hospital mortality.22 To improve the 
quality of facility-based neonatal care in LMICs, a highly 
predictive tool, which is feasible for routine use, is 
needed to help providers objectively assess mortality risk 
in small babies.
This study has two parts: (1) model development using 
data from the UK, and (2) model validation using data 
from the UK and The Gambia. The objectives were to 
evaluate existing neonatal illness severity and mortality 
risk scores to select candidate variables for use in the 
new model; develop and validate a score feasible for use 
in LMICs to predict in-hospital neonatal mortality risk 
among neonates weighing 2000 g or less within 24 h of 
birth; and compare the performance of the novel score 
(NMR-2000) with that of an existing score (CRIB-II).
Methods
Study design and participants
This retrospective study used data held in the UK 
National Neonatal Research Database (NNRD) from 
187 neonatal units to develop a model for scoring in-
hospital neonatal mortality risk in LMICs. The NNRD 
holds de-identified patient-level data, recorded by health-
care providers as part of routine care, from admissions to 
National Health Service neonatal units in England 
starting from 2008, and in Wales and Scotland starting 
from 2012. This study included neonates admitted to 
units in England and Wales between Jan 1, 2010, and 
Dec 31, 2017 (appendix p 1). The following exclusion 
criteria were also applied: birthweight more than 2000 g; 
being admitted at older than 6 h or following discharge 
home; neonates who were stillborn; neonates who died 
in the delivery room; neonates who were moribund 
(received only comfort care before death; appendix p 1).
As well as data from the NNRD, we used data on 
neonates in The Gambia. West and central Africa 
have the highest neonatal mortality worldwide (31 in 
1000 livebirths).1 In The Gambia in 2018, the neonatal 
mortality (26 in 1000 livebirths) ranked ninth among the 
16 countries of west Africa.1 An estimated 12% of 
Gambian neonates are born preterm.3 Edward Francis 
Small Teaching Hospital (EFSTH) in Banjul is the 
national referral hospital where the neo natal unit admits 
around 1400 neonates annually. From 2010 to 2013, 
case-fatality was 35% overall and prematurity-related 
complications were the leading cause of death.23
The Gambian cohort included all neonates weighing 
less than 2000 g who were admitted to EFSTH between 
May 1, 2018, and Sept 30, 2019, who were screened for 
but not enrolled in the Early KMC (eKMC) trial 
(NCT03555981). Some routine data, including mode of 
delivery and treatments administered, were collected 
from medical charts by trained study personnel. Other 
data collected as part of the screening process were 
exported from the trial database, including birthweight, 
sex, birth plurality, referral status, and peripheral 
capillary oxygen saturation (SpO2; appendix p 1).
Model development and validation using the UK dataset 
was approved by the North West–Preston Research Ethics 
Committee (17/NW/0709), the UK Health Research 
Authority, and the London School of Hygiene and Tropical 
Medicine (LSHTM; reference number 14594). Letters were 
sent to the UK Neonatal Collaborative Lead of all units 
contributing data to the NNRD, providing information 
about the study and giving each an opportunity to opt out. 
Model validation using the Gambian dataset was approved 
by research ethics committees of the Gambian Government 
and Medical Research Council Unit The Gambia at the 
LSHTM (reference number 1643) and LSHTM (reference 
number 16189). Consent was not obtained, as this was a 
retrospective study using de-identified data.
Selection of candidate variables
To select the candidate variables for the model, 18 studies 
describing existing systems for assessing neonatal 
mortality risk and illness severity were reviewed to 
generate a list of potential parameters (appendix p 6). 
Parameters that are typically unavailable, infrequently 
obtained, or unreliably measured in low-resource settings 
were excluded (appendix p 1). Remaining parameters 
were evaluated using the following exclusion criteria: low 
prevalence in the NNRD (<0·1%); high proportion of 
missing data in the development dataset (≥20%); not 
predictive of mortality in neonates who are preterm or 
have a low birthweight; low prevalence within the first 
24 h of life; little evidence to support validity; and concept 
better represented by an alternative variable (appendix 
pp 7–9).
Model development
To create the model, we used a development sample of 
neonates admitted to a random sample of neonatal units 
in England and Wales from Jan 1, 2010, to Dec 31, 2016. 
Logistic regression models were derived to model in-
hospital mortality risk. Robust standard errors allowed for 
clustering within units. All candidate variables were 
included in a complete multivariable model, which was 
progressively simplified using reverse stepwise selection, 
with the least statistically significant variable removed at 
each step. Discrimination was assessed with the c-index, 
equivalent to the area under the receiver operating 
characteristic (ROC) curve. A value of 0·5 indicates no 
predictive ability, 0·8 is considered good, and 1 is perfect.21 
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Overall goodness-of-fit was assessed with the Brier score 
and calibration using plots of observed versus predicted 
risk (appendix p 2). Multiple imputation with chained 
equations was used to assess the effect of missing 
data (appendix p 2). The logistic regression model was 
executed across the imputed datasets, and the resulting 
β coefficients and c-index were compared with original 
estimates. A sensitivity analysis excluding neonates 
whose admission age was unknown (anonymised data 
derived from calculated difference between birth time 
and admission time) was done to reassess model 
performance, because admission at more than 6 h of age 
was an exclusion criterion. Performance was additionally 
reassessed follow ing exclusion of neonates who were 
transferred for any reason because outcome data were not 
available for these babies. Performance for predicting 
mortality within 24 h of birth was evaluated in a secondary 
analysis, because 36% of neonatal deaths occur within 
this timeframe.24
Score development
To develop the score, we assigned the parameters in the 
final model points proportional to their β regression 
coefficient values. Whole numbers were used to generate 
an easily calculable score. We arbitrarily defined low-risk, 
medium-risk, and high-risk groups (appendix pp 2–3). To 
assess the calibration of the score to the model using 
regression coefficients, observed risks in groups and 
population deciles of scores were derived and compared 
with mean predicted risks in each group or population 
decile. We assessed overall predictive ability of the score 
using the c-index.
Model validation
We then evaluated both the internal and external 
validity of the model. Internal validity is the reproducibility 
of a prediction model for the underlying population from 
which the data originated.25 Bootstrap resampling with 
1000 samples from within the development sample was 
used to internally validate the model, estimating optimism-
adjusted measures of discrimination and goodness-of-fit 
in each bootstrap sample (appendix p 3). Performance of 
the refitted model in each bootstrap sample was compared 
with that of the refitted model in the original development 
84 parameters in existing neonatal risk scores
45 excluded because infeasible in LMICs
 20 infeasible or often unavailable
 17 infeasible for LMICs and not included in NNRD
 8 infeasible for LMICs and low prevalence
39 parameters remaining
8 excluded
 5 little evidence to support validity
 2 not predictive of mortality in preterm or low birthweight 
 neonates
 1 low prevalence within 24 h of birth
31 parameters remaining
18 parameters selected as candidate variables
13 excluded
 6 better represented by alternative variable
 7 <0·1% prevalence in NNRD, ≥20% missing in 
 development dataset
Figure 1: Flow chart showing filtration of parameters from existing risk 
scores to select candidate variables
LMICs=low-income and middle-income countries. NNRD=National Neonatal 
Research Database.
Panel: Candidate variables evaluated in the modelling 
process
Clinical signs and observations
• Heart rate at admission
• Respiratory rate at admission
• Temperature at admission
• Oxygen saturation (SpO2) at admission
• Convulsions within 24 h of birth, defined as the presence 
of any clinical or electrographic seizures
• Clinically relevant increase in apnoea or brachycardia 
episodes, oxygen requirement, ventilatory support, 
or respiratory rate within 24 h of birth*
Therapy-based variables
• Bag-mask resuscitation at delivery
• Intravenous fluids within 24 h of birth
• Antibiotic therapy within 24 h of birth
• Oxygen therapy within 24 h of birth†
• Highest level of respiratory support administered at any 
point within 24 h of birth‡
• Caffeine (or aminophylline) within 24 h of birth
• Anticonvulsant therapy within 24 h of birth
Perinatal factors
• Sex
• Birthweight
• Gestational age
• Small for gestational age§
• Presence of visually recognisable anomaly at birth¶
SpO2=peripheral capillary oxygen saturation. FiO2=fraction of inspired oxygen. *Defined 
as an increase that was clinically significant enough to necessitate obtaining a culture 
to evaluate for suspected sepsis, at any point within 24 h of birth. †Defined as delivery 
of supplemental oxygen (FiO2 >0·21) via any method at any point within 24 h of birth. 
‡Not including initial resuscitation at birth; level 1 defined as nasal cannula or headbox; 
level 2 defined as continuous positive airway pressure, bilevel or synchronised 
intermittent positive airway pressure, or invasive ventilation with an endotracheal tube 
or tracheostomy. §Defined as birthweight less than the 5th percentile for gestational 
age, using UK-WHO standards.26 ¶Defined as the presence of one or more of the 
following: cleft lip or palate; microcephaly; trisomy 13, trisomy 18, or trisomy 21; 
spina bifida, myelomeningocele, or meningocele; encephalocele; anencephaly; 
holoprosencephaly or prosencephaly; ambiguous genitalia; hypospadias; absent anus; 
gastroschisis; exomphalos or omphalocele; achondroplasia; Noonan syndrome.
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Development sample 
(55 029 eligible neonates; 
112 neonatal units)
External validation samples
Random (40 329 eligible 
neonates; 75 neonatal 
units)
Temporal (14 818 eligible 
neonates; 167 neonatal 
units)
Full (55 147 eligible 
neonates; 173 neonatal 
units)
Birthweight
Extremely low birthweight (<1000 g) 7518 (13·7%) 5705 (14·2%) 2238 (15·1%) 7943 (14·4%)
Very low birthweight (1000–1499 g) 15 475 (28·1%) 11 290 (28·0%) 4198 (28·3%) 15 488 (28·1%)
Low birthweight (1500–2000 g) 32 021 (58·2%) 23 324 (57·9%) 8381 (56·6%) 31 705 (57·5%)
Birthweight data missing* 15 (0·03%) 10 (0·02%) 1 (<0·01%) 11 (0·02%)
Gestational age (weeks)
Extremely preterm (<28) 6969 (12·7%) 5203 (12·9%) 1990 (13·4%) 7193 (13·1%)
Very preterm (28–31) 17 810 (32·4%) 13 108 (32·5%) 4963 (33·5%) 18 071 (32·8%)
Moderate-late preterm (32–36) 28 241 (51·3%) 20 604 (51·1%) 7470 (50·4%) 28 074 (50·9%)
Full term (37–42) 1996 (3·6%) 1408 (3·5%) 393 (2·7%) 1801 (3·3%)
Gestational age data missing 13 (0·02%) 6 (0·02%) 2 (0·01%) 8 (0·01%)
Size at gestation
Small for gestational age 11 039 (20·1%) 7965 (19·8%) 2816 (19·0%) 10 781 (19·6%)
Size at gestation data missing 16 (0·03%) 10 (0·03%) 2 (0·01%) 12 (0·02%)
Sex
Male 27 361 (49·9%) 20 307 (50·4%) 7490 (50·6%) 27 797 (50·4%)
Sex data missing 72 (0·1%) 30 (0·07%) 18 (0·1%) 48 (0·09%)
Mode of delivery
Spontaneous vaginal 16 361 (32·3%) 12 404 (32·6%) 4227 (30·5%) 16 631 (32·0%)
Caesarean section 32 473 (64·1%) 24 404 (64·0%) 9148 (66·1%) 33 552 (64·6%)
Assisted vaginal 1820 (3·6%) 1284 (3·4%) 463 (3·3%) 1747 (3·4%)
Mode of delivery data missing 4375 (8·0%) 2237 (5·5%) 980 (6·6%) 3217 (5·8%)
Multiple birth
Yes 16 933 (30·8%) 12 056 (29·9%) 4442 (30·0%) 16 498 (29·9%)
Multiple birth data missing 22 (0·04%) 8 (0·02%) 2 (0·01%) 10 (0·02%)
Location of birth
Inborn† 53 954 (98·1%) 39 481 (98·0%) 14 476 (97·9%) 53 957 (98·0%)
Location of birth data missing 7 (0·01%) 36 (0·09%) 33 (0·2%) 69 (0·1%)
Location of care
Neonatal intensive care unit‡ 24 018 (43·7%) 22 362 (55·3%) 7506 (50·7%) 29 840 (54·1%)
Local neonatal unit§ 26 276 (47·8%) 13 541 (33·5%) 6054 (40·9%) 19 541 (35·4%)
Special care baby unit¶ 4730 (8·6%) 4538 (11·2%) 1258 (8·5%) 5766 (10·5%)
Location of care data missing 5 (0·01%) 0 (0·0%) 0 (0·0%) 0 (0·0%)
Age at admission (min)
Median (IQR) 21 (13–33) 21 (13–34) 23 (15–35) 22 (14–34)
Age at admission data missing 5 (0·01%) 0 (0·0%) 0 (0·0%) 0 (0·0%)
Disposition
Died before discharge 1653 (3·0%) 1306 (3·2%) 395 (2·8%) 1701 (3·1%)
Extremely low birthweight (<1000 g) 1159 (15·4%) 929 (16·3%) 280 (12·5%) 1209 (15·2%)
Very low birthweight (1000–1499 g) 295 (1·9%) 228 (2·0%) 67 (1·6%) 295 (1·9%)
Low birthweight (1500–2000 g) 199 (0·6%) 149 (0·6%) 48 (0·6%) 197 (0·6%)
Died within 24 h of birth 207 (0·4%) 194 (0·5%) 50 (0·3%) 244 (0·4%)
Transferred to another care unit|| 12 793 (23·3%) 10 119 (25·1%) 4268 (30·3%) 14387 (26·5%)
Disposition data missing 73 (0·1%) 32 (0·1%) 726 (4·9%) 758 (1·4%)
Age at discharge (days)
Median (IQR) 22 (12–38) 21 (11–36) 19 (10–34) 20 (11–36)
Age at discharge data missing 21 (0·04%) 13 (0·03%) 740 (5·0%) 754 (1·4%)
(Table 1 continues on next page)
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sample; estimates of optimism were averaged and sub-
tracted to provide optimism-adjusted measures.
External validity is the generalisability of a model’s 
performance to related populations.25 The model was 
evaluated in three external validation samples: the random 
sample, which included neonates admitted to the units 
withheld from the development sample; the temporal 
sample, which included neonates admitted to units in 
England and Wales from Jan 1, to Dec 31, 2017; and 
the Gambian sample, which included neonates admitted 
to EFSTH between May 1, 2018, and Sept 30, 2019. Each 
sample was used to assess distinctive features of model 
performance. The random sample tested performance in 
different care settings in the UK within the same 
timeframe, whereas the temporal sample tested 
performance during a later timeframe. The Gambian 
sample was used to test performance in a LMIC care 
setting. We assessed model performance in each validation 
sample separately and in the UK full (combined random 
and temporal samples) validation sample. Discrimination 
was evaluated using the c-index, and goodness-of-fit was 
evaluated using the Brier score. Calibration was assessed 
by plotting observed versus predicted risk. We assessed the 
overall predictive ability of the risk score using the c-index. 
Development sample 
(55 029 eligible neonates; 
112 neonatal units)
External validation samples
Random (40 329 eligible 
neonates; 75 neonatal 
units)
Temporal (14 818 eligible 
neonates; 167 neonatal 
units)
Full (55 147 eligible 
neonates; 173 neonatal 
units)
(Continued from previous page)
Variables collected at time of birth
Bag-mask resuscitation at delivery 24 302 (44·2%) 18 297 (45·4%) 6131 (41·4%) 24 428 (44·3%)
Visually recognisable anomaly 1299 (2·4%) 1151 (2·9%) 309 (2·1%) 1460 (2·7%)
Variables collected at time of admission
Heart rate (beats per min), mean (SD) 153·4 (18·4) 153·8 (18·7) 154·5 (18·6) 154·0 (18·6)
Heart rate data missing 7197 (13·1%) 3557 (8·8%) 1234 (8·3%) 4791 (8·7%)
Respiratory rate (breaths per min), mean (SD) 53·3 (29·8) 52·4 (12·9) 52·5 (13·2) 52·4 (13·0)
Respiratory rate data missing 9535 (17·3%) 5377 (13·3%) 2008 (13·6%) 7385 (13·4%)
Temperature (°C), mean (SD) 36·6 (0·7) 36·6 (0·7) 36·7 (0·8) 36·6 (0·7)
Temperature data missing 589 (1·1%) 371 (0·9%) 166 (1·1%) 537 (1·0%)
SpO2 (%), median (IQR) 96 (93–98) 96 (92–99) 96 (93–99) 96 (93–99)
SpO2 data missing 7787 (14·2%) 4213 (10·4%) 1392 (9·4%) 5605 (10·2%)
Variables collected within 24 h of birth
Increased apnoea or bradycardia, oxygen, 
ventilatory support, or respiratory rate
3005 (5·5%) 2458 (6·1%) 903 (6·1%) 3361 (6·1%)
Convulsions 134 (0·3%) 81 (0·2%) 24 (0·2%) 105 (0·2%)
Convulsions data missing 579 (1·1%) 456 (1·1%) 297 (2·0%) 753 (1·4%)
Oxygen therapy 13 998 (25·4%) 10 989 (27·3%) 5178 (34·9%) 16 167 (29·3%)
Highest level of respiratory support
Nasal cannula or headbox 3722 (7·0%) 2758 (7·0%) 2035 (13·9%) 4793 (8.9%)
CPAP, BiPAP or SiPAP, or invasive ventilation 23 374 (43·8%) 16 676 (42·6%) 6427 (43·8%) 23 103 (42·9%)
Respiratory support data missing 1658 (3·0%) 1161 (2·9%) 150 (1·0%) 1311 (2·4%)
Other interventions
Intravenous fluids 41 506 (75·4%) 30 468 (75·6%) 11 697 (78·9%) 42 165 (76·5%)
Antibiotic therapy 39 774 (72·3%) 29 877 (74·1%) 11 152 (75·3%) 41 029 (74·4%)
Caffeine citrate 14 276 (25·9%) 10 862 (26·9%) 5438 (36·7%) 16 300 (29·6%)
Anticonvulsant therapy 162 (0·3%) 150 (0·4%) 45 (0·3%) 195 (0·4%)
Data are complete except where missing data are detailed; missing data are the total number of neonates for whom data are not available. Data are n (%) except where 
otherwise indicated. See panel for definitions of variables. CPAP=continuous positive airway pressure. BiPAP=bilevel positive airway pressure. SiPAP=synchronised intermittent 
positive airway pressure. SpO2=peripheral capillary oxygen saturation. *For neonates whose birthweight was missing, admission weight was used to determine eligibility. 
†Inborn is defined as birth at the hospital of neonatal unit admission. ‡Intensive care units provide care for the sickest neonates who require constant supervision and 
monitoring, including those born at fewer than 27 weeks’ gestational age: care typically includes mechanical ventilation; surgery services offered in some units; care is 
analogous to American Academy of Paediatrics levels 3 and 4.27 §Local neonatal units provide full care for the majority of babies more than 27 weeks’ gestational age, including 
short periods of intensive care; therapies provided include continuous monitoring, CPAP, and parenteral nutrition. ¶Special care units provide care for all other babies who 
could not reasonably be cared for at home; therapies provided include cardiorespiratory monitoring, nasogastric feeding, supplemental oxygen, and phototherapy. ||Transfer 
to another care unit from the initial unit of neonatal admission.
Table 1: Characteristics of the participants in the data samples from the UK National Neonatal Research Database
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In the Gambian sample, we redefined low-risk, medium-
risk, and high-risk groups to account for increased case 
fatality in this sample compared with the UK samples 
(appendix p 3). Observed risks in groups and population 
deciles of scores were derived and compared with mean 
predicted risks in each group or population decile of 
the Gambian sample.
Comparison with the CRIB II score
The NNRD did not include all the variables required for 
calculation of CRIB, SNAP, SNAP-II, SNAPPE-II, TRIPS, 
or TRIPS-II scores (appendix pp 7–9); therefore, CRIB-II 
was selected for comparison with NMR-2000 (appendix p 3). 
Because CRIB-II has only been validated for use in 
neonates born up to 32 weeks’ gestation,18 we compared 
c-indices for CRIB-II and NMR-2000 among neonates 
born at 32 weeks’ gestation or earlier in the full validation 
sample. All analyses were completed using Stata 
(version 15).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
For the selection of candidate variables, 18 studies were 
reviewed to generate a list of 84 potential parameters. 
45 (53·6%) of 84 parameters were considered infeasible 
for LMICs and were excluded, among which, 25 (55·5%) 
also had a low prevalence or were not included in the 
NNRD (figure 1). Eight (9·5%) of 84 parameters were 
excluded because the evidence was scarce, because the 
parameters had poor predictive ability in preterm 
neonates or neonates with low birthweight, or because 
the parameter had a low prevalence within 24 h of birth. 
18 candidate variables were selected for inclusion in the 
modelling process (panel).
110 176 neonates were included in the UK development 
and validation samples. Characteristics of the samples 
and participants are shown in table 1. More than half 
(56·6–58·2%) of the neonates had low birthweight 
(1500–2000 g), 28·0–28·3% had very low birthweight 
(1000–1499 g), and 13·7–15·1% had extremely low 
birthweight (<1000 g). Around half (50·4–51·3%) of the 
neonates were moderate-late preterm (32–36 weeks) and 
one-third (32·4–33·5%) were very preterm (28–31 weeks). 
Overall case-fatality was similar across samples 
(2·8–3·2%). Case-fatality of neonates with extremely low 
birthweight in the temporal sample (280 [12·5%] of 2238) 
was lower than in the other samples. No neonatal units 
declined to contribute data.
Characteristics of the 550 neonates in the Gambian 
validation sample are shown in table 2. Among 
the 550 neonates, 298 (54·2%) had a low birthweight, 
189 (34·4%) had a very low birthweight, and 63 (11·5%) 
had an extremely low birthweight. 142 (25·8%) 
of 550 neonates were multiple births (eg, twins), 
299 (54·5%) of 549 were inborn, and 215 (41·4%) of 
520 died.
The full model (18 variables) had a c-index of 0·9223 in 
the development sample (n=41 514). After stepwise 
elimination, the final model included three variables 
(table 3), with a c-index of 0·8883 and a Brier score of 
0·0232 (table 4). Complete data on all three variables 
were available for 46 108 (83·8%) of 55 029 neonates in 
the development sample. After imputation of missing 
values for predictor variables (n=54 956), the resulting 
β coefficients were nearly identical to original estimates 
(appendix p 9) and model performance was unchanged 
(c-index 0·8894; appendix p 2). Admission age was 
uncertain for 5 (0·01%) of 55 029 neonates; in a sensitivity 
analysis excluding these neonates, there was no change 
in performance (c-index 0·8886, Brier score 0·0232). 
Neonates with 
available data*
Neonates with 
characteristic
Birthweight† 550 (100%) ··
Extremely low birthweight (<1000 g) ·· 63 (11·5%)
Very low birthweight (1000–1499 g) ·· 189 (34·4%)
Low birthweight (1500 to 2000 g) ·· 298 (54·2%)
Sex† 549 (99·8%) ··
Male sex ·· 261 (47·5%)
Mode of delivery† 488 (88·7%) ··
Spontaneous vaginal ·· 342 (70·1%)
Caesarean section ·· 140 (28·7%)
Assisted vaginal ·· 6 (1·2%)
Multiple birth† 550 (100%) ··
Yes ·· 142 (25·8%)
Inborn‡† 549 (99·8%) ··
Yes ·· 299 (54·5%)
Died before discharge† 520 (94·5%) ··
Total ·· 215 (41·4%)
Extremely low birthweight (<1000 g) ·· 55/61 
(90·2%)§
Very low birthweight (1000–1499 g) ·· 93/179 
(52·0%)§
Low birthweight (1500–2000 g) ·· 67/280 
(23·9%)§
Oxygen saturation at admission 513 (93·3%) ··
SpO2 (%) at admission¶ ·· 92% (83–96)
Highest level of respiratory support 
within 24 h of birth†
494 (89·8%) ··
Nasal cannula ·· 294 (59·5%)
CPAP ventilation ·· 53 (10·7%)
Data are n (%), n/N (%), median (IQR). See panel for definition of variables. 
CPAP=continuous positive airway pressure. SpO2=peripheral capillary oxygen 
saturation. *Out of the total 550 neonates. †Information is included on routine 
admission forms. ‡Defined as birth at the study hospital. §Proportion of babies in 
each birthweight category who died (outcome data were not available for 5·5% of 
babies). ¶Information collected for the trial (eKMC trial).
Table 2: Characteristics of participants in the Gambian validation sample
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12 793 (23·3%) of 54 956 neonates were transferred from 
the unit of admission to another care unit; an analysis 
excluding these neonates showed improved performance 
(c-index 0·9150, Brier score 0·0255; appendix p 2). 
Predictive accuracy for mortality within 24 h (c-index 
0·8858, Brier score 0·0037) was nearly identical to that 
for in-hospital mortality. Because availability of SpO2 
monitoring is variable in LMIC settings, we tested a 
related variable (clinically relevant increase in apnoea or 
bradycardia, oxygen requirement, ventilatory support, or 
respiratory rate); however, this variable was not associated 
with in-hospital mortality (c-index 0·5061). A plot of 
observed versus predicted mortality risk in the develop-
ment sample is shown in figure 2.
Birthweight was the most predictive variable in the 
model (c-index 0·8540). The reciprocal of the coefficient 
for birthweight divided by 100 ([1/–0·0032]/100=–3·13) 
was used as the constant to enable retention of exact 
birthweights in score calculation (table 3),28 thereby 
improving predictive ability. The score range for low risk 
was set at 16 or more, for medium risk at 6–15, and for 
high risk at 5 or fewer points (appendix p 9). An example 
score form is shown in figure 3. Among 46 108 neonates 
from the development sample with complete data on the 
three variables included in the final model, 27 289 (59·1%) 
were designated as low risk, 17 215 (37·3%) as medium 
risk, and 1640 (3·6%) as high risk. Observed risks were 
0·3% (95% CI 0·3–0·4) for low risk, 4·1% (3·8–4·4) for 
medium risk, and 27·3% (25·2–29·5) for high risk, with 
a c-index of 0·8875. Mean predicted risks derived from 
regression coefficients were 0·2% (SD 0·2) for low risk, 
4·6% (SD 4·2) for medium risk, and 23·5% (SD 8·8) for 
high risk. Observed risks across population deciles by 
score were similar to the risks predicted with regression 
coefficients (appendix p 10).
After bootstrap resampling, optimism-adjusted 
estimates of c-index and Brier score were nearly 
identical to the original measures; thus, no adjustments 
were made to the coefficients. In the random validation 
sample, complete data on all three parameters were 
available for 35 193 (87·3%) of 40 329 neonates, for 
the temporal validation sample the data were available 
for 12 653 (85·4%) of 14 818 neonates, for the full valid-
ation sample they were available for 47 846 (86·8%) of 
55 147 neonates, and for the Gambian validation sample 
complete data on all three parameters were available for 
457 (83·1%) of 550 neonates. The model showed very 
good performance across the UK validation samples 
(c-index 0·8859–0·8930) and good performance in 
the Gambian validation sample (c-index 0·8170; Brier 
score 0·1688; table 4). Performance was similar among 
neonates weighing 1500 g or less in the Gambian 
sample (c-index 0·8069, Brier score 0·1753).
Graphical plots showed a high level of agreement 
between observed and predicted mortality risk across the 
external validation samples (figure 4). Applying the 
empirical optimal cutpoint of 3·9% based on the Youden 
Index gave moderately high sensitivity (79·1–81·6) and 
β coefficient 95% confidence interval* Integer-points† c-index
Birthweight (g) –0·0032 –0·0035 to –0·0029 Birthweight/100 0·8540
Highest respiratory support 
within first 24 h
·· ·· ·· 0·7529
Nasal cannula or headbox 0·3167 –0·1055 to 0·7389‡ –1 ··
CPAP, BiPAP or SiPAP, 
or invasive ventilation
1·6214 1·2682 to 1·9746‡ –5 ··
SpO2 at admission –0·0390 –0·0455 to –0·0326 ·· 0·6712
<80% (reference level) ·· ·· 0§ ··
80–89% –0·7694 –1·0093 to –0·5294 2§ ··
90–100% –1·3697 –1·6019 to –1·1376 4§ ··
Constant 2·6142¶ 1·7655 to 3·4629 ·· ··
n=46 108. CPAP=continuous positive airway pressure. BiPAP=bilevel positive airway pressure. SiPAP=synchronised 
intermittent positive airway pressure. SpO2=peripheral capillary oxygen saturation. *p<0·0001 for estimates for all 
variables. †Calculated by multiplying the β coefficient by a constant (–3·13) and rounding to the nearest integer. 
The reciprocal of the coefficient for birthweight divided by 100 ([1/–0·0032]/100=–3·13) was used as the constant to 
retain the exact birthweight (per 100 g) in the score. ‡p<0·0001 for overall effect of level of respiratory support. 
§The continuous SpO2 parameter was categorised into clinically meaningful categorical variables; the β coefficients of 
these variables were multiplied by the constant to obtain integer-points; the reference level (<80%) was assigned 
zero points. ¶Reflects β coefficient for constant in model including SpO2 as a continuous variable.
Table 3: Derivation logistic model for the NMR-2000 score
Development sample 
(n=46 108)
External validation samples
Original Optimism-
adjusted*
Random 
(n=35 193)
Temporal 
(n=12 653)
Full 
(n=47 846)
Gambian 
(n=457)
Brier score 0·0232 0·0233 0·0271 0·0240 0·0263 0·1688
c-index 0·8883 0·8882 0·8930 0·8859 0·8912 0·8170
*Because optimism-adjusted estimates of the c-index and Brier score were nearly identical to the original estimates, no 
adjustments were made to the model coefficients.
Table 4: Model performance in the development and validation samples
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Figure 2: Predicted versus observed death for population deciles by predicted 
risk in the development sample
n=46 108. Graph created using pmcalplot.
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specificity (81·0–82·9), with high negative predictive 
value (99·3) and low positive predictive value (11·4–12·2; 
appendix p 10).
The discriminatory ability of the simplified integer score 
was similar to the model using regression coefficients, 
with c-indices of 0·8903 in the full validation sample and 
0·8082 in the Gambian validation sample (appendix p 11). 
Among the 47 846 neonates in the UK full validation 
sample, 28 565 (59·7%) were designated as low risk, 
17 407 (36·4%) as medium risk, and 1874 (3·9%) as high 
risk. Observed risks for these categories were 0·4% 
(95% CI 0·3–0·5) for low risk, 4·8% (4·5–5·1) for medium 
risk, and 29·7% (27·7–31·8) for high risk. In the Gambian 
validation sample, the score range for low risk was set 
at 23 or more, for medium risk at 17–22, and for high 
risk at 16 or fewer points (appendix pp 3, 11). Among the 
457 neonates in the Gambian sample for whom data on 
all three parameters were available, 28 (6·1%) were 
designated as low risk, 215 (47·1%) as medium risk, and 
214 (46·8%) as high risk. Observed risks were 10·7% 
(95% CI 3·5–28·5) for low risk, 21·4% (16·4–27·4) for 
medium risk, and 68·2% (61·7–74·1) for high risk. Mean 
predicted risks derived from regression coefficients were 
9·4% (SD 1·9) for low risk, 22·3% (SD 8·5) for medium 
risk, and 67·4% (SD 18·4) for high risk. Observed risks 
across population deciles by score were similar to those 
predicted with coefficients (appendix p 11).
Comparison of areas under the ROC curves for 
NMR-2000 (c-index 0·8523 [95% CI 0·8336–0·8710]) 
and CRIB-II (c-index 0·7443 [95% CI 0·7153–0·7733]) 
among 10 812 neonates born at 32 weeks’ gestation or 
earlier (figure 5) indicated that discriminatory perfor-
mance of NMR-2000 was superior to that of CRIB-II 
(p<0·0001).
Discussion
This population-wide study, including data from 
110 176 newborn babies at 187 hospitals in the UK and 
550 newborn babies at one hospital in The Gambia, has 
derived and validated NMR-2000 for predicting in-hospital 
mortality. A strength of this work is that, to our knowledge, 
this is the largest dataset that has been used to develop 
and validate a neonatal mortality risk score. Among 
neonates born at 32 weeks’ gestation or earlier, the dis-
criminatory ability of NMR-2000 was superior to that of 
CRIB-II, one of the most widely used neonatal risk scores.
Performance of the NMR-2000 simplified integer 
score, which can be measured and calculated at the 
bedside, was similar to that of the model using regression 
coefficients. The three parameters used in the score can 
be feasibly collected in LMIC settings. Although 
sub-Saharan Africa and southern Asia account for 78% of 
the world’s neonatal deaths,1 existing risk scores have 
primarily been developed for intensive care settings and 
often require complex calculations. In LMICs, where 
parameters in widely used scores are typically not 
available nor reliably measurable,20,21 NMR-2000 could 
support shared decision making by enabling providers to 
objectively assess illness severity.29 The score could be 
used in clinical trials to assess eligibility and compare 
participants.29 Additionally, NMR-2000 could inform 
service delivery planning by identifying bottlenecks in 
care provision.6 Given that 73% of neonatal deaths occur 
within the first 7 days of life,24 early recognition of severe 
illness and rapid initiation of evidence-based inter-
ventions are crucial to promoting survival.5,9,12
The c-index was 0·8859–0·8930 across the development 
and UK validation samples, suggesting that NMR-2000 
can discriminate neonates who will die from neonates 
who will survive. This level of performance is similar to 
that of commonly used neonatal mortality scores in high-
resource settings. Discriminatory ability at the time of 
model derivation ranged from 0·87 for TRIPS-II16 to 0·92 
for CRIB-II.18 Similar to TRIPS-II, NMR-2000 can be 
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Figure 3: NMR-2000, a simplified risk score to predict mortality amongst neonates weighing 2000 g or less
(A) An example mortality risk score for clinical use. (B) Predicted risk of in-hospital mortality plotted against risk 
scores in the development sample; bar data indicate proportion of neonates; blue line indicates predicted mortality 
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assessed at any point within the first 24 h of life and could 
be repeated if the level of respiratory support increases. 
The performance of NMR-2000 (c-index 0·8523) was 
superior to that of CRIB-II (0·7443) among neonates born 
at 32 weeks’ gestation or earlier. The model also showed 
very good predictive ability for mortality within 24 h of 
birth (c-index 0·8858), which is notable because 37% of 
neonatal deaths in sub-Saharan Africa occur within this 
timeframe.24 The NMR-2000 model showed a high level 
of agreement between observed and pred icted deaths, as 
assessed by calibration plots, in the develop ment and 
validation samples. Calibration plots are the preferred 
method for assessing calibration.25 Previous neonatal 
scores, including NTISS,13 SNAPPE-II,15 CRIB-II,18 and 
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Figure 4: Predicted versus observed mortality risk for population deciles in the random, temporal, full, and Gambian validation samples
Graphs created using pmcalplot.
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TRIPS-II,16 were reported to have good calibration 
for predicting in-hospital mortality using the 
Hosmer-Lemeshow test. However, such results should be 
interpreted with caution given the limitations of this test, 
which include subjective and imprecise grouping of 
babies as well as inability to denote the directionality of 
miscalibration when incongruities are detected.25
In the Gambian validation sample, the NMR-2000 model 
had good discrimination and overall goodness-of-fit, with 
c-index of 0·8170 and Brier score of 0·1688. Complete data 
were available for 83% of neonates. The calibration plot 
showed a strong agreement between observed and 
predicted mortality. These findings suggest that NMR-2000 
is valid for use in LMIC settings where pulse oximetry is 
available. Discrimination of the SAWS score, developed for 
neo nates weighing 1500 g or less in low-resource settings, 
at the time of validation (c-index 0·679–0·698)22 was 
decreased relative to NMR-2000 among Gambian neonates 
weighing 1500 g or less (c-index 0·8069). Notably, neither 
goodness-of-fit nor calibration were reported for the SAWS 
score.22 Further, SAWS relies on accurate assessment of 
gestational age, which can be challenging in LMICs 
because of late presentation for antenatal care, poor recall 
of last menstrual period, and unavailability of ultra-
sonography.30 Case-fatality of Gambian neonates in this 
study is similar to that reported from a previous study at 
EFSTH (35% overall, 58% for neonates with a very low 
birthweight),23 and higher than studies at similar hospitals 
in Ghana (20% overall),31 Nigeria (14–20% overall),32,33 and 
Burkina Faso (15% overall).34
Among the three NMR-2000 parameters, all except SpO2 
are included on routine admission forms at EFSTH, 
Gambia (at time of screening),23 as well as standard forms 
at government hospitals in Kenya, Malawi, and Tanzania. 
We were able to obtain SpO2 data for the Gambian sample 
primarily because these data were being collected as part 
of the eKMC trial screening process. Variability in the 
implementation of routine pulse oximetry is a crucial gap 
in low-resource neonatal units.35,36 In a study of nearly 
7500 neonates admitted to 11 hospitals in Nigeria, 
hypoxaemia increased the adjusted odds of mortality by six 
times, and clinical signs (eg, chest in-drawing, grunting) 
poorly predicted hypoxaemia.37 Furthermore, expansion 
of neonatal inpatient care, often of variable quality 
and frequently inclusive of unmonitored 100% oxygen 
supplementation, has placed sub-Saharan Africa on the 
brink of an epidemic of retinopathy of prematurity.38 
Widespread availability of SpO2 monitoring and improved 
coverage of screening for and treatment of retinopathy of 
prematurity will be essential to control the incidence of 
visual loss in affected neonates. In LMIC settings, 
successful implementation of NMR-2000 would require 
sensitisation around recording the three parameters. 
Several studies have highlighted issues surrounding the 
collection of data on neonatal care in LMICs, including 
variable uptake of standard admission forms;36 incomplete 
documentation of assessments, monitoring, and therapies 
prescribed;20,23,36 and low capacity of data systems to capture 
information on neonates who die soon after birth or are 
transferred to another facility.4 Increasing the quality and 
coverage of data is crucial to promote actions to improve 
neonatal survival, and will require coordination across 
different levels of the health-care system.
One strength of this study is our use of a large and 
purposely-selected UK dataset, which enabled maxi-
misation of model performance. One limitation is that 
the Gambian dataset was small and limited to a single 
hospital; research is required to validate the model using 
a larger LMIC dataset. Several candidate variables in the 
development sample had a considerable pro portion of 
missing data, including admission heart rate, respiratory 
rate, and SpO2. It was not possible to compare NMR-2000 
with the CRIB, SNAP, SNAP-II, SNAPPE-II, or TRIPS-II 
scores, because the NNRD did not include all parameters 
required for their calculation. Because pulse oximetry is 
not always available in low-resource neonatal units, the 
usefulness of the NMR-2000 score in such settings could 
be limited. The NNRD did not include clinical signs of 
respiratory distress that could be tested as a potential 
proxy for SpO2. We tested a related variable (clinically 
relevant increase in apnoea or bradycardia, oxygen 
requirement, ventilatory support, or respiratory rate); 
however, this variable was not associated with mortality. 
The use of respiratory support level as a parameter could 
affect the performance of the model. Administration of 
therapies varies in line with variations in clinical practice19 
and resource availability and so might not reflect true 
therapeutic requirements.36 In LMICs, delivery systems 
for oxygen therapy and CPAP might be unavailable or 
non-functional, and related supplies (eg, nasal cannulas) 
might be out of stock.8,35,36
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Figure 5: Comparison of areas under the ROC curves for CRIB-II and NMR-2000
This analysis includes neonates born at 32 weeks’ gestation or earlier in the full 
validation sample (n=10 812). ROC=receiver operating characteristic.
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Research is required to validate the NMR-2000 score in 
low-resource settings using a sufficiently sized dataset, 
and to evaluate its usefulness for supporting clinical 
decision making.29 A follow-up study using a large, 
multihospital dataset from Kenya is planned. Nurses have 
essential roles as frontline providers of neonatal care; 
however, there is a severe shortage of neonatal nurses in 
LMICs.6,7 Future research could explore the model’s ability 
to inform resource use,13 particularly nursing workload.
The NMR-2000 is a simplified risk score, validated for 
high-resource and low-resource settings where pulse 
oximetry is available, to accurately predict in-hospital 
mortality among neonates weighing 2000 g or less. By 
enabling providers to objectively assess illness severity, 
this tool could contribute to improvements in the quality 
of care delivered in LMIC facilities. Early recognition of 
severe illness and rapid initiation of evidence-based 
interventions are crucial to promoting survival of small 
and vulnerable neonates.
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